| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0093-7754(01)90099-5 |
| P698 | PubMed publication ID | 11740803 |
| P2093 | author name string | Demetri GD | |
| P433 | issue | 5 Suppl 17 | |
| P304 | page(s) | 19-26 | |
| P577 | publication date | 2001-10-01 | |
| P1433 | published in | Seminars in Oncology | Q14330412 |
| P1476 | title | Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options | |
| P478 | volume | 28 |
| Q36063055 | A clinical and biological overview of gastrointestinal stromal tumors |
| Q40345307 | A phase II trial of imatinib in patients with refractory/relapsed myeloma |
| Q46500921 | A rare case of rapid growth of exophytic gastrointestinal stromal tumor of the stomach |
| Q35770066 | An update on molecular genetics of gastrointestinal stromal tumours. |
| Q29614538 | Angiogenesis: an organizing principle for drug discovery? |
| Q34974876 | Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development |
| Q35548334 | Biologic directed therapies in gynecologic oncology |
| Q28259527 | Cancer stem cells: the lessons from pre-cancerous stem cells |
| Q45137242 | Clinical management of gastrointestinal stromal tumors |
| Q33959887 | Clinical relevance of KRAS in human cancers |
| Q24561953 | EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib |
| Q47941750 | Emerging Opportunities for Target Discovery in Rare Cancers |
| Q35064126 | Emerging cancer-targeted therapies |
| Q38450888 | Expression of Kit and platelet-derived growth factor receptors α and β in cholangiocarcinoma, and case report of therapy with imatinib mesylate (STI571) |
| Q44544392 | Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium |
| Q37433474 | First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies. |
| Q42106252 | From Transplant to Tablets: A paradigm shift in Oncology |
| Q47265526 | Gastrointestinal Stromal Tumors Respond to Tyrosine Kinase-targeted Therapy |
| Q57649696 | Gastrointestinal stromal tumors |
| Q44157720 | Gastrointestinal stromal tumors (GIST): a prospective evaluation of risk factors and prognostic scores |
| Q81769272 | Gastrointestinal stromal tumors: a seldom diagnosed cause of severe anemia |
| Q80212985 | Gastrointestinal stromal tumors: experience in 49 patients |
| Q34921317 | Gastrointestinal stromal tumors: rationale for surgical adjuvant trials with imatinib |
| Q47096524 | Gastrointestinal stromal tumour presenting with duodenal-jejunal intussusception: a case report |
| Q36426847 | Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment |
| Q41908055 | Genetics of papillary thyroid cancer initiation: implications for therapy |
| Q24814451 | HER-2/neu and CD117 (c-kit) overexpression in patients with pesticide exposure and extensive stage small cell lung carcinoma (ESSCLC). |
| Q46091422 | Immunohistochemical detection of receptor tyrosine kinases c-kit, EGF-R, and PDGF-R in colorectal adenocarcinomas. |
| Q44338521 | Immunohistochemical identification of HER-2/neu overexpression and CD117 (c-kit) expression in multiple myeloma |
| Q42655265 | KIT, PDGFRalpha and EGFR analysis in nephroblastoma |
| Q35877747 | Kinase inhibitors translate lab discoveries into exciting new cures for cancers |
| Q80826939 | Laparoscopic approaches to resection of suspected gastric gastrointestinal stromal tumors based on tumor location |
| Q56906166 | Making Mountains out of Molehills: Moving from Single Gene to Pathway Based Models of Colon Cancer Progression |
| Q90619849 | Mast Cells Populate the Corneoscleral Limbus: New Insights for Our Understanding of Limbal Microenvironment |
| Q36460991 | Modern treatment of gastric gastrointestinal stromal tumors |
| Q36240941 | Molecular chess? Hallmarks of anti-cancer drug resistance |
| Q36791537 | Mutant transcription factors and tyrosine kinases as therapeutic targets for leukemias: from acute promyelocytic leukemia to chronic myeloid leukemia and beyond. |
| Q36911283 | Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy |
| Q36731530 | Pazopanib: a novel multitargeted tyrosine kinase inhibitor |
| Q33278288 | Precancerous stem cells have the potential for both benign and malignant differentiation |
| Q53590924 | Predicting the antitumor effects of STI571 by analysis of c-kit gene mutations in gastrointestinal stromal tumors of the stomach: Report of a case. |
| Q33690657 | Prevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom at different therapeutic lines: an epidemiologic model |
| Q37799935 | Soft tissue sarcoma: from molecular diagnosis to selection of treatment. Pathological diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies |
| Q35778529 | The Jeremiah Metzger Lecture: intelligent design of cancer therapy: trials and tribulations. |
| Q38451399 | The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus |
| Q37373366 | The tumor microenvironment: the making of a paradigm |
| Q37127235 | Translating insights from the cancer genome into clinical practice |
| Q44608405 | Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT |
| Q36261390 | Varied presentations of gastrointestinal stromal tumour. |
| Q45122609 | c-kit Expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications |
Search more.